Pre-clinical evidence for altered absorption and biliary excretion of irinotecan (CPT-11) in combination with quercetin: Possible contribution of P-glycoprotein

Life Sciences

Volumn 83, Issue 7-8, 2008, Pages 250-259

  Bansal, Tripta ^a,b   Awasthi, Anshumali ^b   Jaggi, Manu ^b   Khar, Roop K ^a   Talegaonkar, Sushama ^a  

^a HAMDARD UNIVERSITY   (India)

^b DABUR RESEARCH FOUNDATION   (India)

Author keywords

Caco 2; Irinotecan (CPT 11); P glycoprotein; Pharmacokinetics; Quercetin; SN 38

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CURCUMIN; GLYCOPROTEIN P; HESPERETIN; IRINOTECAN; NARINGENIN; PIPERINE; QUERCETIN;

ANIMAL EXPERIMENT; APICAL MEMBRANE; AREA UNDER THE CURVE; ARTICLE; BASOLATERAL MEMBRANE; BILE FLOW; BILIARY EXCRETION; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG PENETRATION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TRANSPORT; FEMALE; HERB DRUG INTERACTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MONOLAYER CULTURE; NONHUMAN; PLASMA CLEARANCE; PROTEIN FUNCTION; RAT; WISTAR RAT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIOXIDANTS; BILE; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CAMPTOTHECIN; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; INTESTINAL ABSORPTION; P-GLYCOPROTEIN; QUERCETIN; RATS; RATS, WISTAR;

RATTUS; RATTUS NORVEGICUS;

EID: 48749111850     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2008.06.007     Document Type: Article

References (52)

1. Anuchapreeda S., Leechanachai P., Smith M.M., Ambudkar S.V., and Limtrakul P.N. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochemical Pharmacology 64 (2002) 573-582
2. Arimori K., Kuroki N., Hidaka M., Iwakiri T., Yamsaki K., Okumura M., Ono H., Takamura N., Kikuchi M., and Nakano M. Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats. Pharmaceutical Research 20 (2003) 910-917
3. Bailey D., Spence J., Munoz C., and Arnold J. Interaction of citrus juices with felodipine and nifedipine. Lancet 337 (1991) 268-269
4. Bansal T., Singh M., Mishra G., Talegaonkar S., Khar R.K., Jaggi M., and Mukherjee R. Concurrent determination of topotecan and model permeability markers (atenolol, antipyrine, propranolol and furosemide) by reversed phase liquid chromatography: utility in Caco-2 intestinal absorption studies. Journal of Chromatography B 859 (2007) 261-266
5. Bansal, T., Awasthi, A., Jaggi, M., Khar, R.K., Talegaonkar, S., in press, Development and validation of reversed phase liquid chromatographic method utilizing ultraviolet detection for quantification of irinotecan (CPT-11) and its active metabolite, SN-38, in rat plasma and bile samples: Application to pharmacokinetic studies Talanta,, In Press, Accepted Manuscript, Available online 4 May 2008.
6. Bhardwaj R.K., Glaeser H., Becquemont L., Klotz U., Gupta S.K., and Fromm M.F. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. Journal of Pharmacology and Experimental Therapeutics 302 (2002) 645-650
7. Brand W., Schutte M.E., Williamson G., van Zanden J.J., Cnubben N.H., Groten J.P., van Bladeren P.J., and Rietjens I.M. Flavonoid-mediated inhibition of intestinal ABC transporters may affect the oral bioavailability of drugs, food-borne toxic compounds and bioactive ingredients. Biomedicine Pharmacotherapy 60 (2006) 508-519
8. Choi J.S., and Han H.K. Enhanced oral exposure of diltiazem by the concomitant use of naringin in rats. International Journal of Pharmaceutics 305 (2005) 122-128
9. Choi J.S., and Li X. Enhanced diltiazem bioavailability after oral administration of diltiazem with quercetin to rabbits. International Journal of Pharmaceutics 297 (2005) 1-8
10. Choi J.S., and Shin S.C. Enhanced paclitaxel bioavailability after oral coadministration of paclitaxel prodrug with naringin to rats. International Journal of Pharmaceutics 292 (2005) 149-156
11. Choi J.S., Choi H.K., and Shin S.C. Enhanced bioavailability of paclitaxel after oral coadministration with flavone in rats. International Journal of Pharmaceutics 275 (2004) 165-170
12. Choi J.S., Jo B.W., and Kim Y.C. Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. European Journal of Pharmaceutics and Biopharmaceutics 57 (2004) 313-318
13. Chu X.Y., Kato Y., Niinuma K., Sudo K.I., Hakusui H., and Sugiyama Y. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. Journal of Pharmacology and Experimental Therapeutics 281 (1997) 304-314
14. Conseil G., Baubichon-Cortay H., Dayan G., Jault J.M., Barron D., and Di Pietro A. Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein. Proceedings of National Academy of Sciences U S A 95 (1998) 9831-9836
15. Critchfield J.W., Welsh C.J., Phang J.M., and Yeh G.C. Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells. Activation of P-glycoprotein as a putative mechanism. Biochemical Pharmacology 48 (1994) 1437-1445
16. Dantzig A.H., Shepard R.L., Cao J., Law K.L., Ehlhardt W.J., Baughman T.M., Bumol T.F., and Starling J.J. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Research 56 (1996) 4171-4179
17. Dupuy J., Larrieu G., Sutra J.F., Lespine A., and Alvinerie M. Enhancement of moxidectin bioavailability in lamb by a natural flavonoid: quercetin. Veterinary Parasitology 112 (2003) 337-347
18. Gupta E., Safa A.R., Wang X., and Ratain M.J. Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A. Cancer Research 56 (1996) 1309-1314
19. Horikawa M., Kato Y., Tyson C.A., and Sugiyama Y. The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. Drug Metabolism and Pharmacokinetics 17 (2002) 23-33
20. Hsiu S.L., Hou Y.C., Wang Y.H., Tsao C.W., Su S.F., and Chao P.D. Quercetin significantly decreased cyclosporin oral bioavailability in pigs and rats. Life Sciences 72 (2002) 227-235
21. Hu Z., Yang X., Ho P.C., Chan E., Chan S.Y., Xu C., Li X., Zhu Y.Z., Duan W., Chen X., Huang M., Yang H., and Zhou S. St. John's Wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats. Pharmaceutical Research 22 (2005) 902-914
22. Hyafil F., Vergely C., Du Vignaud P., and Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Research 53 (1993) 4595-4602
23. Irvine J.D., Takahashi L., Lockhart K., Cheong J., Tolan J.W., Selick H.E., and Grove J.R. MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening. Journal of Pharmaceutical Sciences 88 (1999) 28-33
24. Itoh T., Itagaki S., Sumi Y., Hirano T., Takemoto I., and Iseki K. Uptake of irinotecan metabolite SN-38 by the human intestinal cell line Caco-2. Cancer Chemotherapy Pharmacology 55 (2005) 420-424
25. Iyer L., Ramirez J., Shepard D.R., Bingham C.M., Hossfeld D.K., Ratain M.J., and Mayer U. Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice. Cancer Chemotherapy Pharmacology 49 (2002) 336-341
26. Jonker J.W., Smit J.W., Brinkhuis R.F., Maliepaard M., Beijnen J.H., Schellens J.H., and Schinkel A.H. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. Journal of National Cancer Institute 92 (2000) 1651-1656
27. Kruijtzer C.M., Beijnen J.H., Rosing H., ten Bokkel Huinink W.W., Schot M., Jewell R.C., Paul E.M., and Schellens J.H. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. Journal of Clinical Oncology 20 (2002) 2943-2950
28. Laitinen L.A., Tammela P.S., Galkin A., Vuorela H.J., Marvola M.L., and Vuorela P.M. Effects of extracts of commonly consumed food supplements and food fractions on the permeability of drugs across Caco-2 cell monolayers. Pharmaceutical Research 21 (2004) 1904-1916
29. Lokiec F., du Sorbier B.M., and Sanderink G.J. Irinotecan (CPT-11) metabolites in human bile and urine. Clinical Cancer Research 2 (1996) 1943-1949
30. Luo F.R., Paranjpe P.V., Guo A., Rubin E., and Sinko P. Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1. Drug Metabolism and Disposition 30 (2002) 763-770
31. Marchetti S., Mazzanti R., Beijnen J.H., and Schellens J.H. Concise review: clinical relevance of drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist 12 (2007) 927-941
32. Mathijssen R.H., van Alphen R.J., Verweij J., Loos W.J., Nooter K., Stoter G., and Sparreboom A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clinical Cancer Research 7 (2001) 2182-2194
33. Meerum Terwogt J.M., Malingre M.M., Beijnen J.H., ten Bokkel Huinink W.W., Rosing H., Koopman F.J., van Tellingen O., Swart M., and Schellens J.H. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clinical Cancer Research 5 (1999) 3379-3384
34. Morris M.E., and Zhang S. Flavonoid-drug interactions: effects of flavonoids on ABC transporters. Life Sciences 78 (2006) 2116-2130
35. Ofer M., Wolffram S., Koggel A., Spahn-Langguth H., and Langguth P. Modulation of drug transport by selected flavonoids: involvement of P-gp and OCT?. European Journal of Pharmaceutical Sciences 25 (2005) 263-271
36. Ofer M., Langguth P., and Spahn-Langguth H. Bidirectional membrane transport: simulations of transport inhibition in uptake studies explain data obtained with flavonoids. European Journal of Pharmaceutical Sciences 29 (2006) 251-258
37. Peng S.X., Ritchie D.M., Cousineau M., Danser E., Dewire R., and Floden J. Altered oral bioavailability and pharmacokinetics of P-glycoprotein substrates by coadministration of biochanin A. Journal of Pharmaceutical Sciences 95 (2006) 1984-1993
38. Shapiro A.B., and Ling V. Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein. Biochemical Pharmacology 53 (1997) 587-596
39. Shin S.C., Choi J.S., and Li X. Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats. International Journal of Pharmaceutics 313 (2006) 144-149
40. Stewart C.F., Leggas M., Schuetz J.D., Panetta J.C., Cheshire P.J., Peterson J., Daw N., Jenkins III J.J., Gilbertson R., Germain G.S., Harwood F.C., and Houghton P.J. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Research 64 (2004) 7491-7499
41. Sugiyama Y., Kato Y., and Chu X. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein. Cancer Chemotherapy Pharmacology 42 (1998) S44-S49 Suppl
42. Takemoto I., Itagaki S., Chiba M., Itoh T., Hirano T., and Iseki K. Characterization of secretory intestinal transport of the lactone form of CPT-11. Cancer Chemotherapy Pharmacology 57 (2006) 129-133
43. Tobin P.J., Hong Y., Seale J.P., Rivory L.P., and McLachlan A.J. Loperamide inhibits the biliary excretion of irinotecan (CPT-11) in the rat isolated perfused liver. Journal of Pharmacy and Pharmacology 57 (2005) 39-45
44. Troutman M.D., and Thakker D.R. Rhodamine 123 requires carrier-mediated influx for its activity as a P-glycoprotein substrate in Caco-2 cells. Pharmaceutical Research 20 (2003) 1192-1199
45. van Asperen J., van Tellingen O., Sparreboom A., Schinkel A.H., Borst P., Nooijen W.J., and Beijnen J.H. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. British Journal of Cancer 76 (1997) 1181-1183
46. Wang Y.H., Chao P.D., Hsiu S.L., Wen K.C., and Hou Y.C. Lethal quercetin-digoxin interaction in pigs. Life Sciences 74 (2004) 1191-1197
47. Yamamoto W., Verweij J., de Bruijn P., de Jonge M.J., Takano H., Nishiyama M., Kurihara M., and Sparreboom A. Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells. Anticancer Drugs 12 (2001) 419-432
48. Yang X., Hu Z., Chan S.Y., Chan E., Goh B.C., Duan W., and Zhou S. Novel agents that potentially inhibit irinotecan-induced diarrhea. Current Medicinal Chemistry 12 (2005) 1343-1358
49. Youdim K.A., Qaiser M.Z., Begley D.J., Rice-Evans C.A., and Abbott N.J. Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radical Biology and Medicine 36 (2004) 592-604
50. Zhang S., Yang X., and Morris M.E. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Molecular Pharmacology 65 (2004) 1208-1216
51. Zhang S., Wang X., Sagawa K., and Morris M.E. Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice. Drug Metabolism Disposition 33 (2005) 341-348
52. Zhou S., Lim L.Y., and Chowbay B. Herbal modulation of P-glycoprotein. Drug Metabolism Reviews 36 (2004) 57-104